Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda

Phase IV commitments should be discussed earlier in the review process to improve the cost-effectiveness of drug development, the Massachusetts Biotechnology Council told FDA Commissioner McClellan